- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00511095
Open-Label Study of the Safety and Immunogenicity of HEPLISAV™ Hepatitis B Virus Vaccine
An Open-Label Study of Safety and Immunogenicity in Subjects Following Injection With Two Doses of HEPLISAV™
Study Overview
Detailed Description
This study will evaluate the safety and efficacy of two injections of HEPLISAV™ in subjects 11 to 55 years old. About 200 subjects will be included in the study. Once subjects have been consented and screened, they will receive a total of two injections over a 28-day period, with follow-up visits at 8, 12 and 28 weeks. Safety and tolerability will be evaluated by occurrence of adverse events, periodic laboratory tests, vital signs, and local/systemic reactogenicity.
Comparison: This study does not include a control treatment; all subjects will receive treatment with HEPLISAV™.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Ohio
-
Boardman, Ohio, United States, 44512
- Beeghley Medical Park
-
-
Pennsylvania
-
Grove City, Pennsylvania, United States, 16127
- Family Healthcare Partners
-
Pittsburgh, Pennsylvania, United States, 15241
- Primary Physicians Research
-
Pittsburgh, Pennsylvania, United States, 15217
- Pediatric Alliance Southwestern
-
Upper Saint Clair, Pennsylvania, United States, 15241
- Family Practice Medical Associates South
-
Washington, Pennsylvania, United States, 15301
- The Washington Hospital Family Medicine
-
-
Virginia
-
Fairfax, Virginia, United States, 22031
- Metropolitan Research
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Willing and able to give written informed consent
- Women of childbearing potential must be willing to consistently use a highly effective method of birth control
Exclusion Criteria:
- Women who are pregnant or breastfeeding
- Any previous HBV infection
- Previous vaccination (1 or more doses) with any HBV vaccine
- Any previous autoimmune diseases
- Are at high risk for recent exposure to HBV, Hepatitis C Virus (HCV) or Human Immunodeficiency Virus (HIV)
- Received any blood products or antibodies within 3 months prior to study entry
- Ever received an injection with DNA plasmids or oligonucleotides
- Received any vaccines within 4 weeks prior to study entry
- Received any other investigational medicinal agent within 4 weeks prior to study entry
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: HEPLISAV
0.5 mL HEPLISAV (20 mcg HBsAg and 3000 mcg 1018) Intramuscular (IM) injection 0.5mL
|
Intramuscular (IM) injections 0.5mL on Day 0 and Week 4
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percentage of Participants With Local and Systemic Post-injection Reaction Rates
Time Frame: Within 7 days post-injection for post-injection reactions at Week 0 and Week 4
|
Local and Systemic post-injection reactions.
|
Within 7 days post-injection for post-injection reactions at Week 0 and Week 4
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percentage of Subjects Who Have a Seroprotective Immune Response (Anti-HBsAg ≥ 10 Milli-international Unit (mIU)/mL) at Weeks 4, 8, 12 and 28.
Time Frame: Weeks 4, 8, 12 and 28
|
Seroprotective Immune Response
|
Weeks 4, 8, 12 and 28
|
|
Serum GMC of Anti-HBsAg Measured at Weeks 4, 8, 12, and 28
Time Frame: Weeks 4, 8, 12, and 28
|
Measurement of Serum GMC
|
Weeks 4, 8, 12, and 28
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Eduardo Martins, MD, DPhil, Dynavax Technologies Corporation
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- DV2-HBV-14
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.